


Hepatitis C: State of Medicaid Access Report Card

Wyoming



Grade	Recommendations to Improve Patient Access
B	<ul style="list-style-type: none">Remove prior authorization for HCV treatment.Remove limit of one course of treatment per lifetime.Remove additional restrictions as described below.

State Overview

As of August 2025, 60,814 individuals were enrolled in Medicaid and CHIP. Wyoming has not expanded coverage to low-income adults.¹ It is estimated that as of 2016, 3,700 people were living with HCV in Wyoming.² Wyoming does not contract with any Managed Care Organizations (MCOs).³ Thus, hepatitis C coverage requirements are uniform throughout the program.

The Wyoming Medicaid Preferred Drug List designates Mavyret and sofosbuvir/velpatasvir as preferred regimens.⁴

Deductions		Policy
Prior Authorization	-8	Prior authorization is required for all HCV treatment regimens. ⁵
Fibrosis Restrictions		Wyoming Medicaid does not impose fibrosis restrictions. ⁶
Substance Use Restrictions		Wyoming Medicaid does not impose substance use restrictions. ⁷
Prescriber Restrictions		Wyoming Medicaid does not impose prescriber restrictions. ⁸
Retreatment Restrictions	-8	Wyoming Medicaid appears to impose retreatment restrictions. The Prior Authorization Form notes that Wyoming allows only one course of treatment per lifetime. ⁹ However, the Preferred Drug List notes that "SVR 12 will be required for consideration for retreatment." ¹⁰
Access in Managed Care		Wyoming does not contract with MCOs. ¹¹
Additional Restrictions	-4	Wyoming Medicaid imposes additional restrictions as follows ¹² : <ul style="list-style-type: none">Documentation of HCV genotype.Documentation of adherence counseling: Wyoming Medicaid requires the prescriber to document patient's ability to adhere to treatment via a psychosocial readiness survey, PREP-C. Additionally, Wyoming Medicaid requires a commitment form to be signed by the patient and provider. The form notes that: "Non-compliance with the prescribed Hepatitis C regimen may put the client in jeopardy for denial of coverage in the future."¹³
Total Deductions -20		Total Score [100-Deductions] 80
		Grade B

Contact Your State Officials

Medicaid Office¹⁴: Jesse Springer, Medicaid Director, Wyoming Department of Health

Mailing Address: 6101 Yellowstone Road, Suite 210, Cheyenne, WY 82009

Pharmacy & Therapeutics Committee¹⁵: Aimee Lewis, DUR Manager, Wyoming Drug Utilization Review

Mailing Address: Dept. 3375, 1000 E. University Ave., Laramie, WY 82071; Phone: 307-766-6750; Email: alewis13@uwyo.edu.

Key Sources

Preferred Drug List: [Wyoming Medicaid, Preferred Drug List \(Sept. 22, 2025\)](#).

Clinical Criteria: Wyoming Medicaid does not publish clinical criteria.

Prior Authorization Form: [Wyoming Medicaid, Prior Authorization Form and Patient Commitment Form \(Jan. 25, 2024\)](#).

¹ Centers for Medicare & Medicaid Services, Medicaid & Chip in Wyoming, <https://www.medicaid.gov/state-overviews/stateprofile.html?state=wyoming>.

² HepVu, Local Data: Wyoming, <https://perma.cc/DLR3-QFJ8>.

³ Kaiser Family Foundation, Share of Medicaid Population Covered Under Different Delivery Systems (Jul. 1, 2022), <https://perma.cc/EMN8-QR8B>.

⁴ Preferred Drug List.

⁵ Preferred Drug List.

⁶ Prior Authorization Form.

⁷ Prior Authorization Form.

⁸ Prior Authorization Form.

⁹ Prior Authorization Form.

¹⁰ Preferred Drug List.

¹¹ Kaiser Family Foundation, Annual Medicaid Budget Survey for State Fiscal Years 2023 and 2024 (Nov. 14, 2023), <https://perma.cc/4K6Y-8DEM>.

¹² Prior Authorization Form.

¹³ Prior Authorization Form.

¹⁴ National Association of Medicaid Directors, <https://medicaiddirectors.org/who-we-are/medicaid-directors/>

¹⁵ Wyoming Drug Utilization Review, <https://www.uwyo.edu/dur/index.html>.